Months after promising Alzheimer’s drug declared a failure, new analysis suggests it was effective

Tara Bahrampour, The Washington Post (US), The National Post (Canada)

Seven months after clinical trials for a promising Alzheimer’s drug were halted and the treatment was declared a failure, a new analysis suggests it was actually effective, and the company that makes it plans to move forward in securing federal approval. The astonishing reversal on aducanumab, an antibody therapy which targets a protein called amyloid beta that builds up in the brain, comes after new data from the discontinued studies showed that at high doses the drug reduced cognitive decline in patients with early Alzheimer’s .“It could be a game-changer for the field,” said Rebecca Edelmayer, director of scientific engagement at the Alzheimer’s Association. “It could be one of the first disease-modifying therapies approved for Alzheimer’s disease.”

Read the rest here: